KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $4.3 billion.

  • West Pharmaceutical Services' Liabilities and Shareholders Equity rose 1719.82% to $4.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $15.9 billion, marking a year-over-year increase of 1066.33%. This contributed to the annual value of $4.3 billion for FY2025, which is 1719.82% up from last year.
  • As of Q4 2025, West Pharmaceutical Services' Liabilities and Shareholders Equity stood at $4.3 billion, which was up 1719.82% from $4.1 billion recorded in Q3 2025.
  • West Pharmaceutical Services' Liabilities and Shareholders Equity's 5-year high stood at $4.3 billion during Q4 2025, with a 5-year trough of $2.7 billion in Q1 2021.
  • For the 5-year period, West Pharmaceutical Services' Liabilities and Shareholders Equity averaged around $3.6 billion, with its median value being $3.6 billion (2022).
  • As far as peak fluctuations go, West Pharmaceutical Services' Liabilities and Shareholders Equity soared by 2262.26% in 2021, and later plummeted by 491.06% in 2024.
  • West Pharmaceutical Services' Liabilities and Shareholders Equity (Quarter) stood at $3.3 billion in 2021, then increased by 9.14% to $3.6 billion in 2022, then rose by 5.88% to $3.8 billion in 2023, then decreased by 4.86% to $3.6 billion in 2024, then increased by 17.2% to $4.3 billion in 2025.
  • Its last three reported values are $4.3 billion in Q4 2025, $4.1 billion for Q3 2025, and $4.0 billion during Q2 2025.